Summary
This phase II trial tests whether poly ICLC works to shrink low-grade gliomas that are growing, spreading, or getting worse (progressive) or that have come back (recurrent) in children and young adults with neurofibromatosis type 1. Poly ICLC, made from ribonucleic acid (RNA), may help the body build an effective immune response to kill tumor cells. Giving poly ICLC may help decrease the size of low-grade gliomas in patients with neurofibromatosis type 1.